Center-Authored Papers

Filters: Author is Kadia, Tapan  [Clear All Filters]
Journal Article
Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A et al..  2016.  Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.. Cancer. 122(12):1871-9. Abstract
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S et al..  2017.  Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.. Blood. 129(10):1275-1283. Abstract
Konopleva M, Thall PF, Arana Yi C, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F et al..  2015.  Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.. Haematologica. Abstract
Konopleva M, Walter RB, Faderl S, Jabbour E, Zeng Z, Borthakur G, Huang X, Kadia T, Ruvolo P, Feliu JB et al..  2014.  Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myeloid Leukemia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 20(8):2226-35. Abstract